REG-Vistin Pharma ASA: Third quarter and YTD 2026 financial results
Globe Newswire•29/10/2026•02:45 ET
0
Key Highlights
- ➤Q3 revenue MNOK 108.4, versus MNOK 108.8 in Q3 2025
- ➤Q3 EBITDA MNOK 19, down from MNOK 28 year over year
- ➤Q3 net profit MNOK 11, versus MNOK 18.5 in Q3 2025
- ➤Additional cash dividend of NOK 0.50 per share approved for November
- ➤No bank debt, MNOK 22 cash, and 78% equity ratio at September-end
Expert Statements
Magnus Tolleshaug, CEO of Vistin Pharma ASA
“We are continuing our sales volume growth focus in 2026, with volumes up 10% year to date compared to 2025 (+420 MT), onboarding new customer volume to utilize manufacturing capacity. Supported by strong cash conversion during 2026, we are also pleased to announce an additional cash dividend of NOK 0.50 per share to our shareholders in Q4.”
Vistin Pharma ASA: Third quarter and YTD 2026 financial results
Vistin Pharma ASA (VISTN) today announces its financial results for the third quarter and year to date 2026.
Get started
Create a free account to read the full story.